Labrafil M 1944 CS

Gelucire® 48/16 Pellets is a non-ionic pure surfactant for lipid-based formulation to solubilize and increase oral bioavailability of poorly soluble API. Forms micellar solution in aqueous media.

Gelucire® 43/01 is a glyceride with an intermediate melting point used as a matrix agent for sensitive APIs and a viscosity-increasing agent in oral and topical formulations.

Gelucire® 44/14 (lauroyl polyoxyl-32 glycerides) is a nonionic water-dispersible surfactant for lipid-based formulations to solubilize and increase oral bioavailability of poorly water-soluble APIs. Self-emulsifies in aqueous media forming a fine dispersion, i.e., microemulsion (SMEDDS).

Gelucire® 50/13 (stearoyl polyoxyl-32 glycerides) is a nonionic water-dispersible surfactant for lipid-based formulations to solubilize and increase oral bioavailability of poorly water-soluble APIs. Self-emulsifies in aqueous media forming a fine dispersion, i.e., microemulsion (SMEDDS).

Labrafac™ lipophile WL 1349 is an oily vehicle and solubilizer of lipophilic APIs for oral, topical, and parenteral lipid-based formulations (LBFs).

Labrafac™ PG is a an oily vehicle and solubilizer for lipophilic APIs in topical dosage forms. Widely used as a vehicle in veterinary parenteral formulations.

Labrafil® M 2125 CS (linoleoyl Polyoxyl-6 glycerides) is a nonionic water-dispersible surfactant for lipid-based formulations to solubilize and increase oral bioavailability of poorly water-soluble APIs. Self-emulsifies in aqueous media forming a coarse dispersion, i.e., emulsion (SEDDS). Co-emulsifier in ...

Labrafil® M 2130 CS (lauroyl polyoxyl-6 glycérides) is a nonionic water-dispersible surfactant for lipid-based formulations to solubilize and increase oral bioavailability of poorly soluble APIs. Self-emulsifies in aqueous media forming a coarse dispersion, i.e., emulsion (SEDDS). Co-emulsifier in topical ...

Labrasol® is a non ionic oil-in-water surfactant used as solubilizer in topical formulations. Solubilizer and O/W surfactant for microemulsion.Able to form light foams with pump device (no gas required).

Labrasol® ALF (caprylocaproyl Polyoxyl-8 glycérides) is a nonionic water-dispersible surfactant for lipid-based formulations to solubilize and increase oral bioavailability of poorly water-soluble APIs. Self-emulsifies in aqueous media forming a fine dispersion, i.e., microemulsion (SMEDDS).

Lauroglycol™ 90 (propylene glycol monolaurate) is a nonionic water-insoluble surfactant used as cosurfactant in oral lipid-based formulation SEDDS and SMEDDS. Cosurfactant and solubilizer in topical dosage forms.

Lauroglycol™ FCC is a nonionic water-insoluble surfactant used as cosurfactant in oral lipid-based formulation SEDDS and SMEDDS. Cosurfactant and solubilizer in topical dosage forms associated with skin penetration enhancement.

Discover Gelucire® 59/14, an add-on in Gattefossé Gelucire® range, for oral bioavailability enhancement

Selecting best excipient

Discover Labrafac™ MC60, glycerol monocaprylocaprate, an oral bioavailability enhancer.

This session was originally broadcast as part of the CPHI Worldwide 2021 digital content programme. Patient adherence to skin treatments Bi-gels: formulating new topical drugs Emulfree® Duo, a ready-to-use excipient designed to make bi-gels Case studies

Discover our brand new excipient Emulfree® Duo, a ready-to-use stabilizing agent, enabler of bi-gel, an emerging topical dosage form.

This session was originally broadcast as part of the CPHI Worldwide 2021 digital content programme. This session explores: Using Lipid-based formulations to address oral bioavailability issues Labrafac™ MC60, glycerol monocaprylocaprate, Gattefossé new bioehancer Case study: step-by-step development of a lipid-based formulation of dutasteride with Labrafac™ MC60 Gattefossé technical expertise

Many drugs exhibit poor solubility and/or permeability leading to weak oral bioavailability. To overcome these issues, different technologies have been developed. Among them, lipid-based formulation (LBF) is an option worth considering as it can be used from the very beginning of drug development to product, reducing time to market.